@media(max-width: 600px) {.adace_adsense_5a54ecf8be6d9 {display:block !important;}}
@media(min-width: 601px) {.adace_adsense_5a54ecf8be6d9 {display:block !important;}}
@media(min-width: 801px) {.adace_adsense_5a54ecf8be6d9 {display:block !important;}}
@media(min-width: 961px) {.adace_adsense_5a54ecf8be6d9 {display:block !important;}}
(adsbygoogle = window.adsbygoogle || []).push({});
These days, when Mexico and the United States are mentioned in the same sentence, it usually has something to do with President Trump building a wall. So it’s a little bit ironic that Mexico beat the U.S. to tearing down the wall between its citizens and access to legal medical marijuana. On June 21, 2017, Mexican President Enrique Peña Nieto signed a decree legalizing medical cannabis in the country, with the strong support of the nation’s Lower House of Congress. [1]
Thomas Marino, U.S. Representative for Pennsylvania’s 10th congressional districts, is interviewed in his office in Washington, D.C. Jan. 2, 2012 (Jake Danna Stevens, The Times-Tribune/AP
President Donald Trump’s reported choice to serve as Director of the Office of National Drug Control Policy has raised alarm concerning conflict of interest, as his top pick has been criticized for protecting and benefiting from the pharmaceutical industry.
